Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

NCT04214860 is registered in ClinicalTrials.gov with Aprea Therapeutics as lead sponsor.

NCT NCT04214860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04214860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Lead sponsor
Aprea Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 13, 2019
Completion date
January 14, 2022
Enrollment
51 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid malignancy